Losartan kidney failure
Pro Research Analysisby 
Searched over 200M research papers
Losartan and Kidney Failure: A Comprehensive Review
Introduction to Losartan and Kidney Health
Losartan, an angiotensin II receptor antagonist, is widely used to manage hypertension and protect renal function. This article synthesizes research findings on the effects of losartan on kidney failure, particularly in patients with diabetes, hypertension, and acute kidney injury (AKI).
Losartan in Diabetic Nephropathy
Renal Benefits in Type 2 Diabetes
Losartan has shown significant renal benefits in patients with type 2 diabetes and nephropathy. A large-scale study involving 1513 patients demonstrated that losartan reduced the incidence of doubling serum creatinine concentration by 25% and end-stage renal disease (ESRD) by 28% compared to placebo . Additionally, losartan significantly decreased proteinuria by 35%, indicating its protective effect on kidney function beyond blood pressure control .
Long-term Effects and Safety
A follow-up analysis of the RENAAL trial indicated that losartan therapy reduced the risk of ESRD and hospitalizations for heart failure across all stages of type 2 diabetic nephropathy . This suggests that losartan is effective and well-tolerated even in patients with advanced chronic kidney disease (CKD).
Losartan in Hypertension and Renal Dysfunction
Prevention of Renal Damage
Losartan has been shown to prevent renal damage induced by hypertension and insulin resistance. In a study with fructose-overloaded rats, losartan prevented metabolic and hemodynamic alterations, reduced pro-inflammatory and pro-fibrotic markers, and prevented microalbuminuria . This highlights losartan's role in maintaining renal health in hypertensive conditions.
Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD)
Research indicates that losartan can mitigate the progression from AKI to CKD. In a murine model, losartan administration post-AKI significantly reduced mortality, blood pressure, albuminuria, azotemia, and kidney fibrosis compared to controls . This suggests that losartan can be beneficial in reducing long-term kidney damage following AKI.
Losartan and Renal Ischemia/Reperfusion Injury
Protective Effects
Losartan has demonstrated protective effects against renal ischemia/reperfusion (I/R) injury. Studies on rats showed that losartan administration before and after I/R injury reduced serum urea nitrogen, creatinine, and kidney tissue damage . This indicates that losartan can protect against acute renal injury by modulating oxidative stress and inflammation.
Antioxidant Properties
In hypertensive rats, losartan improved antioxidant defense mechanisms, increased creatinine and urea clearance, and reduced lipid peroxidation and kidney necrosis after ischemic injury . These findings underscore the potential of losartan in enhancing renal recovery and function post-ischemia.
Clinical Considerations and Safety
Pharmacokinetics in End-Stage Renal Disease (ESRD)
The pharmacokinetics of losartan and its active metabolite E-3174 are minimally altered in patients with ESRD, indicating that dosage adjustments are not necessary for these patients . This makes losartan a viable option for managing hypertension in individuals with advanced renal failure.
Potential Risks
While losartan is generally well-tolerated, there are reports of renal impairment in patients with preexisting renal conditions or those on concomitant medications like diuretics . Clinicians should monitor renal function closely in at-risk patients to prevent adverse outcomes.
Conclusion
Losartan offers significant renal protection in various conditions, including diabetic nephropathy, hypertension-induced renal damage, and post-acute kidney injury. Its benefits extend to reducing proteinuria, preventing ESRD, and improving antioxidant defenses. However, careful monitoring is essential in patients with preexisting renal impairment to avoid potential risks. Overall, losartan remains a valuable therapeutic agent in preserving kidney health and preventing renal failure.
Sources and full results
Most relevant research papers on this topic
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Losartan significantly reduces the risk of kidney damage and end-stage renal disease in patients with type 2 diabetes and nephropathy, while maintaining overall cardiovascular health.
Losartan prevents the imbalance between renal dopaminergic and renin angiotensin systems induced by fructose overload. l-Dopa/dopamine index as new potential biomarker of renal dysfunction.
Losartan effectively prevents the imbalance between the renin angiotensin and renal dopaminergic systems induced by fructose overload, preventing hypertension and kidney damage.
Losartan Improved Antioxidant Defense, Renal Function and Structure of Postischemic Hypertensive Kidney
Losartan blockade improves kidney function and structure in postischemic hypertensive rats, potentially benefiting patients with acute renal failure.
Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure
GGN1231 shows potential in preventing cardiovascular damage, cardiac hypertrophy, and fibrosis in a rat model of chronic renal failure, with a non-significant 20% reduction in mortality.
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Losartan therapy effectively reduces the risk of ESRD and heart failure in individuals with type 2 diabetes and overt nephropathy, and is well-tolerated at all levels of renal function.
Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial
Early losartan treatment showed no significant long-term benefit in slowing kidney disease progression in American Indians with type 2 diabetes.
DOI